Swiss pharmaceutical company Novartis is laying off more than one in ten employees in Switzerland over the next three years – 1,400 of 11,600 jobs will go. It also plans to cut 8,000 of 108,000 jobs worldwide.
This content was published on
2 minutes
Keystone-SDA/ts
Español
es
Novartis eliminará 1 400 puestos de trabajo en Suiza
On Tuesday the Basel-based company informed its employees in detail about the wave of redundancies for the first time. All sites are affected.
Novartis confirmed corresponding reports by TA-Media newspapers in response to an enquiry from news agency AWP.
At the beginning of April Novartis announced a comprehensive restructuring, which it hopes will result in savings of at least $1 billion (CHF960 million) by 2024. The centrepiece is the merger of the previously separate divisions Innovative Pharmaceuticals and Cancer Drugs.
In addition to adapting its operational structure, Novartis is also simplifying its global functions in finance, human resources, legal and communications. This will eliminate positions across the company, according to a spokesperson.
“Novartis is making rapid progress in implementing these changes across the organisation and has already completed the appointment of most leadership teams at the global level,” he said.
The spokesperson added that the company was aware of the impact of these changes on employees and was ensuring that all consultation requirements were met, through representative bodies where appropriate.
In Switzerland, formal consultations with employee representatives at the non-management level and consultations with management in the affected areas were already underway, he said.
More
More
Novartis: The making of a pharma giant
This content was published on
The company formed when Ciba Geigy and Sandoz merged and analysts say it’s a big success. The merger cost around 10,000 jobs but in the long-run more were created. The current CEO concedes that the merger also meant the loss of the Ciba corporate identity. Novartis’ profits shrank by a third in 2015, partly because…
Direct trains to run from Zurich to Florence and Livorno
This content was published on
The Swiss Federal Railways and Trenitalia will offer direct trains from Zurich to Florence and Livorno and vice versa from 2026.
Number of Swiss armed forces exceeds specified limit
This content was published on
The Swiss armed forces had an effective headcount of around 147,000 as of March 1, 2024. This exceeds the upper limit of 140,000 specified in the army organisation by 5%.
More than 400,000 cross-border commuters now work in Switzerland
This content was published on
More than half of all cross-border commuters were resident in France (around 57%). Large proportions also lived in Italy (23%) and Germany (around 16%).
Amherd and von der Leyen discuss ongoing Swiss-EU negotiations
This content was published on
Swiss President Viola Amherd and EU Commission President Ursula von der Leyen have met and talked about the ongoing negotiations between Bern and Brussels.
This content was published on
One million francs, 34 million euros and around 830 kilos of gold: this is the fortune that two Swiss nationals are accused of having moved across borders for at least four years.
Girls in female-dominated classes earn more later on
This content was published on
At the age of 30, women from school classes with a 55% share of girls earn $350 more per year than women from classes with a 45% share of girls.
This content was published on
Geneva-based luxury goods group Richemont reported a downturn in performance for the first half of its 2024/25 financial year. Both sales and profit declined.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis to cut 2,200 Swiss jobs by 2020
This content was published on
Around 1,500 jobs are affected in production and 700 in services. Novartis currently employs 13,000 people across Switzerland.
This content was published on
Swiss pharmaceutical firm Novartis filed the most international trademark applications with the World Intellectual Property Organization (WIPO) .
Novartis pays big fine for bribing doctors in the US
This content was published on
Swiss pharma company Novartis will pay $729 million to US authorities in an out-of-court settlement over charges that the company bribed doctors to use its drugs.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.